SCHEMBL23948509

SCHEMBL23948509

COc1ccoc1CCCCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAOB P27338 8/20 0.51
BCHE P06276 3/20 0.49
ACHE P22303 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
CYP3A4 P08684 1/20 0.49
HTR1A P08908 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALOX12 P18054 1/20 0.49
ADRA1D P25100 1/20 0.49
HTR7 P34969 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
KMT2A Q03164 1/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29263694 0.79 MAOB (0.69) TDP1L3MBTL1MAOBBCHEACHE
SCHEMBL9053567 0.75 ALDH1A1 (0.67) TDP1L3MBTL1ALDH1A1
SCHEMBL14121833 0.74 TSHR (0.66) L3MBTL1MAOBBCHEACHEALDH1A1
SCHEMBL8863154 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL8862728 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL8863094 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL6777483 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL2604742 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL8862878 0.73 TDP1 (0.75) TDP1L3MBTL1ACHEMEN1KMT2A
SCHEMBL11373726 0.72 HPGD (0.63) TDP1L3MBTL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
WO-2021211984-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS GLUL, TGM2, GLS TDP1 1498/4885L3MBTL1 1138/4885MAOB 1490/4885
US-11701427-B2 Diels-alder conjugation methods GLUL, TGM2, GLS TDP1 1498/4885L3MBTL1 1138/4885MAOB 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.